Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 20, 2016

View Archived Issues

AstraZeneca completes IND-supporting studies of IONIS-KRAS-2.5R

CHMP grants positive opinion to acknowledge that Jardiance reduces the risk of CV death

Board recommends continuation of MediciNova's phase IIb trial of ibudilast

CHMP grants positive opinion for Alecensa for the treatment of NSCLC

Jiangsu Tasly Diyi Pharmaceutical patents CD26 inhibitors

Japanese approval sought for romosozumab to treat osteoporosis

Yeungnam University discloses agents for inflammatory bowel disease

Qingdao Marine Biomedical Research Institute describes agents for cancer

Parsabiv approved in Japan

Presage Biosciences develops autophagy inhibitors

Owen-Barry Pharmaceuticals presents sodium channel blockers

EMA validates Sarepta's MAA for eteplirsen in Duchenne muscular dystrophy

CHMP grants positive opinion for Truxima

Novartis and Conatus sign option, collaboration and license agreement for emricasan

Shionogi & Co. and Purdue Pharma enter naldemedine agreement

Adaptimmune Therapeutics and Bellicum Pharmaceuticals enter strategic agreement

Phase III COMPASS study of volanesorsen in severe hypertriglyceridemia meets primary endpoint

FDA approves Rubraca and companion diagnostic for ovarian cancer

Formation Biologics presents novel cancer candidates

Spero Therapeutics begins phase I study of SPR-471

IRAK antagonist shows promise for L265P-mutant CNS lymphomas

AbbVie submits NDA for glecaprevir/pibrentasvir

Profounda gets FDA orphan drug designation for miltefosine in treatment of acanthamoeba keratitis

Tetra Discovery reports positive results on BPN-14770

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 19, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 19, 2025.
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...